

R_3 is H, $-SO_2$ (C₁₋₆ alkyl), $-SO_2$ phenyl, (C=O)(C₁₋₆ alkyl), or $-W'Z'$;
 W' is a covalent bond, (C=O), SO₂, or C₁₋₆ alkyl;
 Z' is C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₈ cycloalkyl, phenyl, or a heterocyclic radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl C₂₋₆ heterocyclic radical, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, N, NH, S, SO, and SO₂; or Z' is NR₁₃R₁₄ where each of R₁₃ and R₁₄ is independently selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl C₂₋₅ heterocyclic radical; each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, nitro, or amino; one of R_a, R_b, R_c, R_d, and R_e is WZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, nitro, and amino; W is -O-, R₉, O-R₉, NR₁₀, -(CO)(O)R₉, -O(CO)R₉, -(CO)NR₁₀, or -N(R₁₀)-CO-R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ a heterocyclic bivalent radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl, and R₁₀

is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or a heterocyclic radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholiny|C₂₋₅ heterocyclic radical;

Z is a heterocyclic radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholiny|C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N, CSR₁₅; or Z is NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholiny|C₂₋₅ heterocyclic radical; or NR₁₁R₁₂ taken together is a C₆₋₈ cycloalkylimino radical; and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, and C₄₋₇ cycloalkenyl; each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, C₁₋₃ alkoxy, halo, hydroxy, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be

attached to the rest of the molecule by a carbon atom or a heteroatom;
provided that R_b, R_d, R₅, R₆, R₇ and R₈, if halo, are selected from chloro;
or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. (original) A compound of claim 1, wherein R₃ is H or C₁₋₃ alkyl.
3. (original) A compound of claim 1, wherein R₃ is -(C=O)C₁₋₆ alkyl.
4. (original) A compound of claim 1, wherein R₃ is -SO₂(C₁₋₃ alkyl).
5. (original) A compound of claim 4 wherein R₃ is methylsulfonyl.
6. (original) A compound of claim 1, wherein W' is a covalent bond.
7. (original) A compound of claim 1, wherein W' is SO₂ or (C=O).
8. (original) A compound of claim 1, wherein R_c is WZ.
9. (original) A compound of claim 1, wherein R_b or R_d is WZ.
10. (original) A compound of claim 1, wherein W is ethoxy, propoxy, or butoxy.
11. (original) A compound of claim 1, wherein W is -O-.
12. (original) A compound of claim 1, wherein one of R_b, R_c, and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, nitro, and halo; and R_a and R_d are each independently H or methyl.

13. (original) A compound of claim 1, wherein at least two of the following apply: R_c is WZ; W is propoxy or ethoxy; and Z is N-piperidino, 2-(N-methyl)pyrrolidino, or N,N-dimethyl.
14. (currently amended) A compound of claim 1, wherein Z is pyrrolidino, N-methyl-pyrrolidino, pyridyl, thiazoyl, piperidino, or NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₆ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoaxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl_{G-2-5} heterocyclic radical or taken together with the N form a C₆₋₈ cycloalkylamino radical.
15. (currently amended) A compound of claim 1, wherein one of R_b, R_c, and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, and halo; and R_a and R_d are each independently H or methyl; W is -O- or C₁₋₃ alkoxy; Z is pyrrolidino, N-methylpyrrolidino, pyridyl, thiazoyl, piperidino, piperazino, N-methylpiperazino, or NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₂ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoaxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl_{G-2-5} heterocyclic radical; each of R₆ and R₇ are each independently H, methyl, methoxy, or ethoxy; each of R₅ and R₈ is H.

16. (original) A compound of claim 15, wherein R₃ is H or -SO₂ (C₁₋₆ alkyl).
17. (original) A compound of claim 15, wherein R₃ is SO₂ (phenyl) and (C=O)(C₁₋₆ alkyl).
18. (original) A compound of claim 15, selected from 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1H-indole, 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1-(methylsulfonyl)-1H-indole, and 2-[4-[3-Piperidinopropoxy]phenyl]-1H-indole;) 2-(4-(3-(4-methylpiperazino)propoxy)-phenyl)indole; and 1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)-propoxy)phenyl)indole; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.
19. (original) A compound of claim 15, selected from 2-[4-[3-Piperidinopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole, and 2-[3-[3-Piperidinopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.
20. (original) A pharmaceutical composition comprising a compound of formula (I)B and a pharmaceutically acceptable carrier.
21. (currently amended) A pharmaceutical composition of claim 20, wherein said compound has a formula wherein: one of R_b, R_c, and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, and halo; R_a and R_d are each independently H or methyl; W is -O- or C₁₋₃ alkoxy; Z is pyrrolidino, N-methylpyrrolidino, pyridyl, thiazoyl, piperidino, or NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₂ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and a heterocyclic radical selected from the group consisting of thiazoylyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl,

isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl,
isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl,
pyrrolinyl, imdazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl,
piperidyl, piperazinyl, indolinyl, and morpholinyl^{C-2-5-heterocyclic}
radical; and

R₆ and R₇ are each independently H, methyl, methoxy, or ethoxy.

22. (original) A pharmaceutical composition of claim 21, wherein said compound has a formula selected from 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1H-indole; 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1-(methylsulfonyl)-1H-indole; 2-[4-[3-Piperidinoproxy]phenyl]-1H-indole; 2-[4-[3-Piperidinoproxy]phenyl]-1-(methylsulfonyl)-1H-indole; 2-[3-[3-Piperidinoproxy]phenyl]-1-(methylsulfonyl)-1H-indole; 2-(4-(3-(4-methylpiperazino)propoxy)-phenyl)indole; and 1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)propoxy)phenyl)indole; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.
23. (cancelled)
24. (cancelled)
25. (cancelled)
26. (cancelled)
27. (cancelled)
28. (cancelled)
29. (cancelled)
30. (cancelled)

31. (cancelled)

32. (cancelled)